What are the recommended treatment options for osteopenia and osteoporosis?

Treatment for Osteopenia and Osteoporosis

Osteoporosis Treatment

For patients with confirmed osteoporosis (T-score ≤ -2.5), oral bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab should be initiated as first-line therapy to reduce hip and vertebral fracture risk 1, 2, 3.

Risk Stratification Determines Treatment Intensity

Treatment selection must be based on fracture risk level:

High Risk Patients (10-year major osteoporotic fracture risk ≥20% or hip fracture risk ≥3%):

• First-line options: Alendronate, risedronate, zoledronate, or denosumab 1
• Alternate therapy: Ibandronate or raloxifene 1

Very High Risk Patients (prior fracture, advanced age, frailty, very low T-scores, glucocorticoid use, increased fall risk):

• Preferred initial therapy: Anabolic agents (abaloparatide, romosozumab, or teriparatide) followed by antiresorptive therapy 1, 2
• Alternative: Denosumab or zoledronate 1
• Sequential therapy starting with bone-forming agents followed by antiresorptives is strongly recommended for this group 2

Specific Medication Recommendations

Oral Bisphosphonates (First-line for most patients):

• Alendronate 70 mg weekly or risedronate 35 mg weekly 2, 4
• Treat for 5 years initially, then reassess 3
• Consider drug holiday after 5 years if fracture risk is no longer high (T-score > -2.5, fracture-free) 5
• Can continue up to 10 years in very high-risk patients 5

Intravenous Bisphosphonates:

• Zoledronic acid 5 mg annually 4
• Consider drug holiday after 3 years in high-risk patients or after 6 years in very high-risk patients 5

Denosumab (Second-line or specific situations):

• 60 mg subcutaneously every 6 months 2, 4
• Critical warning: Never discontinue denosumab without transitioning to another antiresorptive agent due to rapid rebound bone loss and increased vertebral fracture risk 5, 6
• Must be followed by bisphosphonate therapy if stopped 5

Anabolic Agents (Very high-risk patients):

• Teriparatide or abaloparatide: Limit to 2 years maximum 5
• Romosozumab: Limit to 1 year maximum 5
• Must be followed by bisphosphonate or denosumab to prevent bone density decline 5

Men with Osteoporosis

Oral bisphosphonates (alendronate or risedronate) are first-line treatment for men at high fracture risk 2. Denosumab or zoledronate serve as second-line options 2. All men with prior fragility fracture should be considered for treatment 2.

Essential Baseline Support

All patients require:

• Calcium: 1,000-1,200 mg daily (age-dependent) 4
• Vitamin D: 600-800 IU daily (target serum level ≥20 ng/mL) 4
• Weight-bearing exercise and fall prevention strategies 2, 5
• Smoking cessation and alcohol moderation 4

Monitoring and Follow-up

• Reassess yearly for response to therapy and fracture risk 1
• Do not routinely monitor BMD during the initial 5-year treatment period 3
• Bone turnover markers can assess compliance and treatment response (target: at or below premenopausal median for antiresorptives) 5

Treatment Failure Management

If fractures occur or BMD declines despite therapy:

• Assess compliance first 1
• Re-evaluate for secondary causes of osteoporosis 1
• Switch to injectable antiresorptive if on oral agent 1
• Switch to anabolic therapy (abaloparatide, romosozumab, or teriparatide) if on injectable antiresorptive 1

---

Osteopenia Treatment

For osteopenia (T-score between -1.0 and -2.5), treatment decisions must be based on absolute fracture risk using FRAX, not T-score alone 3, 4.

Treatment Thresholds for Osteopenia

Pharmacologic treatment should be initiated when:

• 10-year major osteoporotic fracture risk ≥20% OR
• 10-year hip fracture risk ≥3% 3, 4
• Prior low-trauma fracture (even without osteoporosis on BMD) 4

For osteopenic patients meeting these thresholds:

• Use same first-line bisphosphonate options as osteoporosis 3
• Treatment selection should consider patient preferences, fracture risk profile, and medication benefits/harms 3

Osteopenia Below Treatment Threshold

For osteopenic patients NOT meeting FRAX thresholds:

• Calcium and vitamin D optimization (same doses as above) 4
• Weight-bearing and resistance exercise 3-5 miles walking weekly 7
• Lifestyle modifications: smoking cessation, alcohol moderation 4
• Repeat BMD in 1-2 years to monitor for progression 5

Important caveat: The majority of osteoporotic fractures actually occur in individuals with osteopenic T-scores, but the number needed to treat is much higher (NNT >100) compared to established osteoporosis (NNT 10-20) 8. Therefore, widespread treatment based on T-score alone is not advisable—absolute fracture risk assessment is essential.

Medications to Avoid

Do not use menopausal estrogen therapy, estrogen plus progestogen therapy, or raloxifene as primary osteoporosis treatment due to increased cardiovascular and thromboembolic risks 3. Exception: HRT may be considered first-line in younger postmenopausal women with high fracture risk and low baseline risk for adverse events 9.